United States President Donald Trump announced this Friday that U.S. health officials have approved the use of the antiviral drug remdesivir to treat patients with COVID-19, the disease caused by the coronavirus.
Trump made this announcement at a White House appearance with FDA director Stephen Hahn, who made sure the antiviral was available to all approved American COVID-19 patients Hospitals.
The FDA has approved the emergency use of this experimental treatment after some patients treated with remdesivir had a faster recovery from coronavirus infection.
The FDA made this decision after preliminary results from a Gilead Sciences laboratory study with Redemsivir showed that this antiviral shortened the hospital stay of COVID-19 patients by an average of four days. , according to the CBS television station.
The study was conducted on a sample of 1,063 patients. This was the largest and most rigorous study with this drug and included a comparison group in which patients received the usual treatment without this drug.